All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
This article summarizes the discussion on the results of the TOURMALINE-MM4 trial, held between Mohamad Mohty, María-Victoria Mateos, and Karthik Ramasamy at a live virtual journal club organized by the International Academy for Clinical Hematology (IACH).1
The TOURMALINE-MM4 trial was reported during this year’s European Hematology Association (EHA) Annual Congress and the American Society of Clinical Oncology (ASCO) Annual Meeting, indicating the clear survival benefit of ixazomib for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). These results were recently published in the Journal of Clinical Oncology by Meletios Dimopoulos and colleagues2 and reported on the Multiple Myeloma Hub here.
Subscribe to get the best content related to multiple myeloma delivered to your inbox